JOHNSON & JOHNSON - FORM 8-K - EX-99.2O - EXHIBIT

Attached files

file	filename
8-K - 8-K - JOHNSON & JOHNSON	a2013q38kcover.htm
EX-99.15 - EXHIBIT - JOHNSON & JOHNSON	a2013q38kexhibit9915.htm

Exhibit 99.2O



Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	THIRD QUARTER

	2013				2012						Percent
				Percent					Percent		Increase
	Amount			to Sales	Amount				to Sales		(Decrease)
Sales to customers	$	17,575		100.0	$	17,052			100.0		3.1
Cost of products sold	5,344			30.4	5,597				32.8		(4.5	)
Selling, marketing and administrative expenses	5,314			30.2	5,228				30.6		1.6
Research and development expense	2,042			11.6	1,923				11.3		6.2
In-process research and development	178			1.0	679				4.0
Interest (income) expense, net	87			0.5	120				0.7
Other (income) expense, net	943			5.4	(90		)		(0.5	)
Earnings before provision for taxes on income	3,667			20.9	3,595				21.1		2.0
Provision for taxes on income	685			3.9	966				5.7		(29.1	)
Net earnings	2,982			17.0	2,629				15.4		13.4
Add: Net loss attributable to noncontrolling interest	—			—	339				2.0
Net earnings attributable to Johnson & Johnson	$	2,982		17.0	$	2,968			17.4		0.5

Net earnings per share attributable to Johnson & Johnson (Diluted)	$	1.04			$	1.05					(1.0	)

Average shares outstanding (Diluted)	2,881.2				2,818.1

Effective tax rate	18.7		%		26.9			%

Adjusted earnings before provision for taxes and net earnings attributable to Johnson & Johnson^{(1) (A)}
Earnings before provision for taxes on income	$	4,831		27.5	$	4,525			26.5		6.8
Net earnings attributable to Johnson & Johnson	$	3,919		22.3	$	3,521			20.6		11.3
Net earnings per share attributable to Johnson & Johnson (Diluted)	$	1.36			$	1.25					8.8
Effective tax rate	18.9		%		22.2			%

⁽¹⁾See Reconciliation of Non-GAAP Financial Measures.

^(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings attributable to Johnson & Johnson," "adjusted net earnings per share attributable to Johnson & Johnson (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings attributable to Johnson & Johnson, net earnings per share attributable to Johnson & Johnson (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings attributable to Johnson & Johnson, net earnings per share attributable to Johnson & Johnson (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings attributable to Johnson & Johnson, adjusted net earnings per share attributable to Johnson & Johnson (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses the performance of the Company. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.



Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	NINE MONTHS

	2013				2012				Percent
				Percent				Percent	Increase
	Amount			to Sales	Amount			to Sales	(Decrease)
Sales to customers	$	52,957		100.0	$	49,666		100.0	6.6
Cost of products sold	16,387			30.9	15,655			31.5	4.7
Selling, marketing and administrative expenses	15,913			30.0	15,208			30.6	4.6
Research and development expense	5,772			10.9	5,334			10.7	8.2
In-process research and development	242			0.5	1,108			2.2
Interest (income) expense, net	292			0.6	379			0.8
Other (income) expense, net	1,630			3.1	1,307			2.7
Earnings before provision for taxes on income	12,721			24.0	10,675			21.5	19.2
Provision for taxes on income	2,409			4.5	2,728			5.5	(11.7	)
Net earnings	10,312			19.5	7,947			16.0	29.8
Add: Net loss attributable to noncontrolling interest	—			—	339			0.7
Net earnings attributable to Johnson & Johnson	$	10,312		19.5	$	8,286		16.7	24.5

Net earnings per share attributable to Johnson & Johnson (Diluted)	$	3.58			$	2.96			20.9

Average shares outstanding (Diluted)	2,879.0				2,805.0

Effective tax rate	18.9		%		25.6		%

Adjusted earnings before provision for taxes and net earnings attributable to Johnson & Johnson^{(1) (A)}
Earnings before provision for taxes on income	$	15,260		28.8	$	14,099		28.4	8.2
Net earnings attributable to Johnson & Johnson	$	12,315		23.3	$	10,969		22.1	12.3
Net earnings per share attributable to Johnson & Johnson (Diluted)	$	4.28			$	3.91			9.5
Effective tax rate	19.3		%		22.2		%

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.

^(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings attributable to Johnson & Johnson," "adjusted net earnings per share attributable to Johnson & Johnson (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings attributable to Johnson & Johnson, net earnings per share attributable to Johnson & Johnson (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings attributable to Johnson & Johnson, net earnings per share attributable to Johnson & Johnson (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings attributable to Johnson & Johnson, adjusted net earnings per share attributable to Johnson & Johnson (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses the performance of the Company. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	THIRD QUARTER
				Percent Change
	2013		2012	Total			Operations		Currency
Sales to customers by
segment of business

Consumer
U.S.	$	1,225	1,214	0.9		%	0.9		—
International	2,386		2,367	0.8			2.6		(1.8	)
	3,611		3,581	0.8			2.0		(1.2	)

Pharmaceutical
U.S.	3,549		3,288	7.9			7.9		—
International	3,487		3,114	12.0			14.0		(2.0	)
	7,036		6,402	9.9			10.9		(1.0	)

Med Devices & Diagnostics
U.S.	3,151		3,289	(4.2	)		(4.2	)	—
International	3,777		3,780	(0.1	)		4.2		(4.3	)
	6,928		7,069	(2.0	)		0.3		(2.3	)

U.S.	7,925		7,791	1.7			1.7		—
International	9,650		9,261	4.2			7.1		(2.9	)
Worldwide	$	17,575	17,052	3.1		%	4.7		(1.6	)



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	NINE MONTHS
				Percent Change
	2013		2012	Total		Operations	Currency
Sales to customers by
segment of business

Consumer
U.S.	$	3,899	3,843	1.5	%	1.5	—
International	7,045		6,952	1.3		2.7	(1.4	)
	10,944		10,795	1.4		2.3	(0.9	)

Pharmaceutical
U.S.	10,397		9,408	10.5		10.5	—
International	10,432		9,418	10.8		12.9	(2.1	)
	20,829		18,826	10.6		11.7	(1.1	)

Med Devices & Diagnostics
U.S.	9,600		9,119	5.3		5.3	—
International	11,584		10,926	6.0		10.0	(4.0	)
	21,184		20,045	5.7		7.9	(2.2	)

U.S.	23,896		22,370	6.8		6.8	—
International	29,061		27,296	6.5		9.2	(2.7	)
Worldwide	$	52,957	49,666	6.6	%	8.1	(1.5	)



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	THIRD QUARTER
					Percent Change
	2013		2012		Total			Operations	Currency
Sales to customers by
geographic area

U.S.	$	7,925	7,791		1.7		%	1.7	—

Europe	4,478		3,983		12.4			8.4	4.0
Western Hemisphere excluding U.S.	1,842		1,824		1.0			8.0	(7.0	)
Asia-Pacific, Africa	3,330		3,454		(3.6	)		5.1	(8.7	)
International	9,650		9,261		4.2			7.1	(2.9	)

Worldwide	$	17,575	$	17,052	3.1		%	4.7	(1.6	)



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	NINE MONTHS
					Percent Change
	2013		2012		Total		Operations	Currency
Sales to customers by
geographic area

U.S.	$	23,896	22,370		6.8	%	6.8	—

Europe	13,631		12,342		10.4		8.6	1.8
Western Hemisphere excluding U.S.	5,530		5,266		5.0		10.3	(5.3	)
Asia-Pacific, Africa	9,900		9,688		2.2		9.2	(7.0	)
International	29,061		27,296		6.5		9.2	(2.7	)

Worldwide	$	52,957	$	49,666	6.6	%	8.1	(1.5	)



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

	Third Quarter						% Incr. /
(Dollars in Millions Except Per Share Data)	2013			2012			(Decr.)

Earnings before provision for taxes on income - as reported	$	3,667		3,595			2.0		%

Litigation expenses	872			89

In-process research and development	178			679

Synthes integration/transaction costs and currency related	122			165		⁽¹⁾

DePuy ASR™ Hip program	35			27

Intangible asset write-downs	—			—

Other	(43		)	(30	)

Earnings before provision for taxes on income - as adjusted	$	4,831		4,525			6.8		%

Net Earnings attributable to Johnson & Johnson - as reported	$	2,982		2,968			0.5		%

Litigation expenses	720			70

In-process research and development	126			340		⁽²⁾

Synthes integration/transaction costs and currency related	103			135

DePuy ASR™ Hip program	31			24

Intangible asset write-downs	—			—

Other	(43		)	(16	)

Net Earnings attributable to Johnson & Johnson - as adjusted	$	3,919		3,521			11.3		%

Diluted Net Earnings per share attributable to Johnson & Johnson - as reported	$	1.04		1.05			(1.0	)	%

Litigation expenses	0.25			0.02

In-process research and development	0.04			0.13

Synthes integration/transaction costs and currency related	0.04			0.05

DePuy ASR™ Hip program	0.01			0.01

Intangible asset write-downs	—			—

Other	(0.02		)	(0.01	)

Diluted Net Earnings per share attributable to Johnson & Johnson - as adjusted	$	1.36		1.25			8.8		%


⁽¹⁾ Represents inventory step-up recorded in cost of products sold

⁽²⁾ In-process research and development of $679M offset by $339M reported as net loss attributable to noncontrolling interest

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision
for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

	Nine Months YTD						% Incr. /
(Dollars in Millions Except Per Share Data)	2013			2012			(Decr.)

Earnings before provision for taxes on income - as reported	$	12,721		$	10,675		19.2	%

Litigation expenses	1,776			758

In-process research and development	242			1,108

Synthes integration/transaction costs and currency related	502			622

DePuy ASR™ Hip program	117			27

Intangible asset write-downs	—			939

Other	(98		)	(30		)

Earnings before provision for taxes on income - as adjusted	$	15,260		14,099			8.2	%

Net Earnings attributable to Johnson & Johnson - as reported	$	10,312		8,286			24.5	%

Litigation expenses	1,419			681

In-process research and development	168			684

Synthes integration/transaction costs and currency related	373			593

DePuy ASR™ Hip program	122			24

Intangible asset write-downs	—			717

Other	(79		)	(16		)

Net Earnings attributable to Johnson & Johnson - as adjusted	$	12,315		10,969			12.3	%

Diluted Net Earnings per share attributable to Johnson & Johnson - as reported	$	3.58		2.96			20.9	%

Litigation expenses	0.49			0.24

In-process research and development	0.06			0.24

Synthes integration/transaction costs and currency related	0.13			0.21

DePuy ASR™ Hip program	0.04			0.01

Intangible asset write-downs	—			0.26

Other	(0.02		)	(0.01		)

Diluted Net Earnings per share attributable to Johnson & Johnson - as adjusted	$	4.28		3.91			9.5	%


The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision
for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		THIRD QUARTER
				% Change
		2013	2012	Reported		Operational⁽¹⁾		Currency
CONSUMER SEGMENT^{(2) (4)}

BABY CARE
US	$	99	104	(4.8	)%	(4.8	)%	—	%
Intl		461	460	0.2		4.3		(4.1	)
WW		560	564	(0.7	)	2.6		(3.3	)

ORAL CARE
US		142	162	(12.3)		(12.3)		—
Intl		253	251	0.8		3.2		(2.4	)
WW		395	413	(4.4	)	(3.0	)	(1.4	)

OTC⁽³⁾
US		310	263	17.9		17.9		—
Intl		665	653	1.8		2.0		(0.2	)
WW		975	916	6.4		6.5		(0.1	)

SKIN CARE
US		404	390	3.6		3.6		—
Intl		520	514	1.2		2.1		(0.9	)
WW		924	904	2.2		2.7		(0.5	)

WOMEN'S HEALTH
US		77	81	(4.9	)	(4.9	)	—
Intl		331	326	1.5		4.3		(2.8	)
WW		408	407	0.2		2.5		(2.3	)

WOUND CARE/OTHER⁽³⁾
US		193	214	(9.8	)	(9.8	)	—
Intl		156	163	(4.3	)	(3.0	)	(1.3	)
WW		349	377	(7.4	)	(6.9	)	(0.5	)

TOTAL CONSUMER
US		1,225	1,214	0.9		0.9		—
Intl		2,386	2,367	0.8		2.6		(1.8	)
WW	$	3,611	3,581	0.8	%	2.0	%	(1.2	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		THIRD QUARTER
				% Change
		2013	2012	Reported		Operational⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4)}

IMMUNOLOGY
US	$	1,648	1,600	3.0	%	3.0	%	—	%
Intl		695	484	43.6		47.7		(4.1	)
WW		2,343	2,084	12.4		13.4		(1.0	)
REMICADE
US		1,013	940	7.8		7.8		—
US Exports⁽⁵⁾		291	379	(23.2	)	(23.2	)	—
Intl		385	272	41.5		46.1		(4.6	)
WW		1,689	1,591	6.2		7.0		(0.8	)
SIMPONI
US		111	93	19.4		19.4		—
Intl		155	92	68.5		74.9		(6.4	)
WW		266	185	43.8		47.0		(3.2	)
STELARA
US		233	188	23.9		23.9		—
Intl		137	99	38.4		38.6		(0.2	)
WW		370	287	28.9		29.0		(0.1	)
OTHER IMMUNOLOGY
US		—	—	—		—		—
Intl		18	21	(14.3	)	(8.1	)	(6.2	)
WW		18	21	(14.3	)	(8.1	)	(6.2	)

INFECTIOUS DISEASES
US		278	259	7.3		7.3		—
Intl		543	536	1.3		(0.1	)	1.4
WW		821	795	3.3		2.4		0.9
INCIVO
US		—	—	—		—		—
Intl		76	71	7.0		5.3		1.7
WW		76	71	7.0		5.3		1.7
INTELENCE
US		47	45	4.4		4.4		—
Intl		45	49	(8.2	)	(9.2	)	1.0
WW		92	94	(2.1	)	(2.6	)	0.5
PREZISTA
US		215	181	18.8		18.8		—
Intl		195	183	6.6		4.4		2.2
WW		410	364	12.6		11.5		1.1
OTHER INFECTIOUS DISEASES
US		16	33	(51.5	)	(51.5	)	—
Intl		227	233	(2.6	)	(3.4	)	0.8
WW		243	266	(8.6	)	(9.3	)	0.7

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		THIRD QUARTER
				% Change
		2013	2012	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

NEUROSCIENCE
US	$	601	678	(11.4	)%	(11.4	)%	—	%
Intl		991	990	0.1		4.6		(4.5	)
WW		1,592	1,668	(4.6	)	(1.9	)	(2.7	)
CONCERTA/METHYLPHENIDATE
US		38	150	(74.7	)	(74.7	)	—
Intl		104	104	0.0		3.5		(3.5	)
WW		142	254	(44.1	)	(42.7	)	(1.4	)
INVEGA
US		82	78	5.1		5.1		—
Intl		65	62	4.8		11.0		(6.2	)
WW		147	140	5.0		7.8		(2.8	)
INVEGA SUSTENNA/XEPLION
US		180	130	38.5		38.5		—
Intl		144	82	75.6		72.9		2.7
WW		324	212	52.8		51.7		1.1
RISPERDAL CONSTA
US		114	113	0.9		0.9		—
Intl		212	238	(10.9	)	(8.7	)	(2.2	)
WW		326	351	(7.1	)	(5.6	)	(1.5	)
OTHER NEUROSCIENCE
US		187	207	(9.7	)	(9.7	)	—
Intl		466	504	(7.5	)	(0.7	)	(6.8	)
WW		653	711	(8.2	)	(3.4	)	(4.8	)

ONCOLOGY
US		227	145	56.6		56.6		—
Intl		754	483	56.1		57.1		(1.0	)
WW		981	628	56.2		57.0		(0.8	)
VELCADE
US		—	—	—		—		—
Intl		404	327	23.5		26.3		(2.8	)
WW		404	327	23.5		26.3		(2.8	)
ZYTIGA
US		204	136	50.0		50.0		—
Intl		260	129	*		97.1		4.5
WW		464	265	75.1		72.9		2.2
OTHER ONCOLOGY
US		23	9	*		*		—
Intl		90	27	*		*		(5.2	)
WW		113	36	*		*		(3.8	)
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		THIRD QUARTER
				% Change
		2013	2012	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

TOTAL OTHER
US	$	795	606	31.2	%	31.2	%	—	%
Intl		504	621	(18.8	)	(18.8	)	0.0
WW		1,299	1,227	5.9		5.9		0.0
ACIPHEX/PARIET
US		89	80	11.3		11.3		—
Intl		44	115	(61.7	)	(62.0	)	0.3
WW		133	195	(31.8	)	(32.0	)	0.2
PROCRIT/EPREX
US		204	198	3.0		3.0		—
Intl		140	161	(13.0	)	(14.4	)	1.4
WW		344	359	(4.2	)	(4.8	)	0.6
XARELTO
US		246	68	*		*		—
Intl		—	—	—		—		—
WW		246	68	*		*		—
OTHER
US		256	260	(1.5	)	(1.5	)	—
Intl		320	345	(7.2	)	(6.4	)	(0.8	)
WW		576	605	(4.8	)	(4.4	)	(0.4	)

TOTAL PHARMACEUTICAL
US		3,549	3,288	7.9		7.9		—
Intl		3,487	3,114	12.0		14.0		(2.0	)
WW	$	7,036	6,402	9.9	%	10.9	%	(1.0	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		THIRD QUARTER
				% Change
		2013	2012	Reported		Operational ⁽¹⁾		Currency
MEDICAL DEVICES AND DIAGNOSTICS ⁽²⁾

CARDIOVASCULAR CARE
US	$	196	195	0.5	%	0.5	%	—	%
Intl		305	298	2.3		6.6		(4.3	)
WW		501	493	1.6		4.2		(2.6	)

DIABETES CARE
US		237	328	(27.7	)	(27.7	)	—
Intl		320	301	6.3		6.5		(0.2	)
WW		557	629	(11.4	)	(11.3	)	(0.1	)

DIAGNOSTICS
US		222	256	(13.3	)	(13.3	)	—
Intl		237	257	(7.8	)	(2.8	)	(5.0	)
WW		459	513	(10.5	)	(8.0	)	(2.5	)

INFECTION PREVENTION/OTHER
US		91	98	(7.1	)	(7.1	)	—
Intl		129	134	(3.7	)	4.3		(8.0	)
WW		220	232	(5.2	)	(0.5	)	(4.7	)

ORTHOPAEDICS
US		1,232	1,242	(0.8	)	(0.8	)	—
Intl		1,051	1,048	0.3		3.4		(3.1	)
WW		2,283	2,290	(0.3	)	1.1		(1.4	)

SPECIALTY SURGERY
US		321	308	4.2		4.2		—
Intl		305	289	5.5		9.2		(3.7	)
WW		626	597	4.9		6.7		(1.8	)

SURGICAL CARE
US		587	602	(2.5	)	(2.5	)	—
Intl		947	949	(0.2	)	3.9		(4.1	)
WW		1,534	1,551	(1.1	)	1.4		(2.5	)

VISION CARE
US		265	260	1.9		1.9		—
Intl		483	504	(4.2	)	4.9		(9.1	)
WW		748	764	(2.1	)	3.9		(6.0	)

TOTAL MEDICAL DEVICES AND DIAGNOSTICS
US		3,151	3,289	(4.2	)	(4.2	)	—
Intl		3,777	3,780	(0.1	)	4.2		(4.3	)
WW	$	6,928	7,069	(2.0	)%	0.3	%	(2.3	)%
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		NINE MONTHS
				% Change
		2013	2012	Reported		Operational⁽¹⁾		Currency
CONSUMER SEGMENT^{(2) (4)}

BABY CARE
US	$	308	309	(0.3	)%	(0.3	)%	—	%
Intl		1,402	1,373	2.1		5.2		(3.1	)
WW		1,710	1,682	1.7		4.2		(2.5	)

ORAL CARE
US		449	476	(5.7	)	(5.7	)	—
Intl		755	732	3.1		4.8		(1.7	)
WW		1,204	1,208	(0.3	)	0.8		(1.1	)

OTC ⁽³⁾
US		954	801	19.1		19.1		—
Intl		1,995	1,949	2.4		2.7		(0.3	)
WW		2,949	2,750	7.2		7.4		(0.2	)

SKIN CARE
US		1,320	1,314	0.5		0.5		—
Intl		1,414	1,410	0.3		0.9		(0.6	)
WW		2,734	2,724	0.4		0.7		(0.3	)

WOMEN'S HEALTH
US		242	254	(4.7	)	(4.7	)	—
Intl		978	964	1.5		4.2		(2.7	)
WW		1,220	1,218	0.2		2.4		(2.2	)

WOUND CARE/OTHER ⁽³⁾
US		626	689	(9.1	)	(9.1	)	—
Intl		501	524	(4.4	)	(3.8	)	(0.6	)
WW		1,127	1,213	(7.1	)	(6.8	)	(0.3	)

TOTAL CONSUMER
US		3,899	3,843	1.5		1.5		—
Intl		7,045	6,952	1.3		2.7		(1.4	)
WW	$	10,944	10,795	1.4	%	2.3	%	(0.9	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		NINE MONTHS
				% Change
		2013	2012	Reported		Operational⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4)}

IMMUNOLOGY
US	$	4,865	4,524	7.5	%	7.5	%	—	%
Intl		1,923	1,374	40.0		43.3		(3.3	)
WW		6,788	5,898	15.1		15.9		(0.8	)
REMICADE
US		2,909	2,712	7.3		7.3		—
US Exports⁽⁵⁾		972	1,123	(13.4	)	(13.4	)	—
Intl		1,080	800	35.0		38.2		(3.2	)
WW		4,961	4,635	7.0		7.5		(0.5	)
SIMPONI
US		292	220	32.7		32.7		—
Intl		386	206	87.4		95.3		(7.9	)
WW		678	426	59.2		63.0		(3.8	)
STELARA
US		692	469	47.5		47.5		—
Intl		395	287	37.6		38.5		(0.9	)
WW		1,087	756	43.8		44.1		(0.3	)
OTHER IMMUNOLOGY
US		—	—	—		—		—
Intl		62	81	(23.5	)	(21.4	)	(2.1	)
WW		62	81	(23.5	)	(21.4	)	(2.1	)

INFECTIOUS DISEASES
US		775	738	5.0		5.0		—
Intl		1,831	1,600	14.4		14.7		(0.3	)
WW		2,606	2,338	11.5		11.7		(0.2	)
INCIVO
US		—	—	—		—		—
Intl		410	305	34.4		36.1		(1.7	)
WW		410	305	34.4		36.1		(1.7	)
INTELENCE
US		138	130	6.2		6.2		—
Intl		146	135	8.1		8.1		0.0
WW		284	265	7.2		7.2		0.0
PREZISTA
US		578	507	14.0		14.0		—
Intl		634	554	14.4		14.0		0.4
WW		1,212	1,061	14.2		14.0		0.2
OTHER INFECTIOUS DISEASES
US		59	101	(41.6	)	(41.6	)	—
Intl		641	606	5.8		6.0		(0.2	)
WW		700	707	(1.0	)	(0.8	)	(0.2	)

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		NINE MONTHS
				% Change
		2013	2012	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

NEUROSCIENCE
US	$	1,973	2,010	(1.8	)%	(1.8	)%	—	%
Intl		3,043	3,019	0.8		4.6		(3.8	)
WW		5,016	5,029	(0.3	)	2.0		(2.3	)
CONCERTA/METHYLPHENIDATE
US		262	493	(46.9	)	(46.9	)	—
Intl		351	337	4.2		6.6		(2.4	)
WW		613	830	(26.1	)	(25.1	)	(1.0	)
INVEGA
US		229	223	2.7		2.7		—
Intl		200	180	11.1		16.9		(5.8	)
WW		429	403	6.5		9.1		(2.6	)
INVEGA SUSTENNA/XEPLION
US		502	350	43.4		43.4		—
Intl		396	218	81.7		80.1		1.6
WW		898	568	58.1		57.5		0.6
RISPERDAL CONSTA
US		327	336	(2.7	)	(2.7	)	—
Intl		670	731	(8.3	)	(6.1	)	(2.2	)
WW		997	1,067	(6.6	)	(5.1	)	(1.5	)
OTHER NEUROSCIENCE
US		653	608	7.4		7.4		—
Intl		1,426	1,553	(8.2	)	(2.8	)	(5.4	)
WW		2,079	2,161	(3.8	)	0.1		(3.9	)

ONCOLOGY
US		632	371	70.4		70.4		—
Intl		2,028	1,439	40.9		42.9		(2.0	)
WW		2,660	1,810	47.0		48.6		(1.6	)
VELCADE
US		—	—	—		—		—
Intl		1,136	998	13.8		16.7		(2.9	)
WW		1,136	998	13.8		16.7		(2.9	)
ZYTIGA
US		539	349	54.4		54.4		—
Intl		664	348	90.8		89.1		1.7
WW		1,203	697	72.6		71.7		0.9
OTHER ONCOLOGY
US		93	22	*		*		—
Intl		228	93	*		*		(5.7	)
WW		321	115	*		*		(4.6	)
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		NINE MONTHS
				% Change
		2013	2012	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

TOTAL OTHER
US	$	2,152	1,765	21.9	%	21.9	%	—	%
Intl		1,607	1,986	(19.1	)	(18.7	)	(0.4	)
WW		3,759	3,751	0.2		0.4		(0.2	)
ACIPHEX/PARIET
US		289	280	3.2		3.2		—
Intl		152	369	(58.8	)	(58.7	)	(0.1	)
WW		441	649	(32.0	)	(32.0	)	0.0
PROCRIT/EPREX
US		627	634	(1.1	)	(1.1	)	—
Intl		430	502	(14.3	)	(14.9	)	0.6
WW		1,057	1,136	(7.0	)	(7.3	)	0.3
XARELTO
US		593	144	*		*		—
Intl		—	—	—		—		—
WW		593	144	*		*		—
OTHER
US		643	707	(9.1	)	(9.1	)	—
Intl		1,025	1,115	(8.1	)	(7.2	)	(0.9	)
WW		1,668	1,822	(8.5	)	(7.9	)	(0.6	)

TOTAL PHARMACEUTICAL
US		10,397	9,408	10.5		10.5		—
Intl		10,432	9,418	10.8		12.9		(2.1	)
WW	$	20,829	18,826	10.6	%	11.7	%	(1.1	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		NINE MONTHS
				% Change
		2013	2012	Reported		Operational ⁽¹⁾		Currency
MEDICAL DEVICES AND DIAGNOSTICS ⁽²⁾

CARDIOVASCULAR CARE
US	$	598	566	5.7	%	5.7	%	—	%
Intl		945	913	3.5		7.5		(4.0	)
WW		1,543	1,479	4.3		6.8		(2.5	)
DIABETES CARE
US		779	1,017	(23.4	)	(23.4	)	—
Intl		967	955	1.3		2.2		(0.9	)
WW		1,746	1,972	(11.5	)	(11.0	)	(0.5	)
DIAGNOSTICS
US		711	767	(7.3	)	(7.3	)	—
Intl		708	772	(8.3	)	(4.1	)	(4.2	)
WW		1,419	1,539	(7.8	)	(5.7	)	(2.1	)
INFECTION PREVENTION/OTHER
US		271	313	(13.4	)	(13.4	)	—
Intl		395	393	0.5		6.9		(6.4	)
WW		666	706	(5.7	)	(2.1	)	(3.6	)
ORTHOPAEDICS
US		3,767	2,898	30.0		30.0		—
Intl		3,286	2,513	30.8		34.3		(3.5	)
WW		7,053	5,411	30.3		31.9		(1.6	)
SPECIALTY SURGERY
US		971	971	0.0		0.0		—
Intl		938	900	4.2		7.2		(3.0	)
WW		1,909	1,871	2.0		3.4		(1.4	)
SURGICAL CARE
US		1,695	1,797	(5.7	)	(5.7	)	—
Intl		2,935	3,019	(2.8	)	0.6		(3.4	)
WW		4,630	4,816	(3.9	)	(1.8	)	(2.1	)
VISION CARE
US		808	790	2.3		2.3		—
Intl		1,410	1,461	(3.5	)	4.3		(7.8	)
WW		2,218	2,251	(1.5	)	3.6		(5.1	)

TOTAL MEDICAL DEVICES AND DIAGNOSTICS
US		9,600	9,119	5.3		5.3		—
Intl		11,584	10,926	6.0		10.0		(4.0	)
WW	$	21,184	20,045	5.7	%	7.9	%	(2.2	)%
*Percentage greater than 100%
⁽¹⁾Operational growth excludes the effect of currency
⁽²⁾ Unaudited
⁽³⁾ Nutritionals now reflected in Wound Care/Other, previously reported in OTC/Nutritionals
⁽⁴⁾Prior year amounts have been reclassified to conform to current year product disclosure
⁽⁵⁾Reported as U.S. sales

Attached files

Stock widget

Investing forum

JOHNSON & JOHNSON Reports

Also read

JOHNSON & JOHNSON - FORM 8-K - EX-99.2O - EXHIBIT - October 15, 2013

Attached files

Stock widget

Investing forum

JOHNSON & JOHNSON Reports

Also read